Disease Domain | Count |
---|---|
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 2 |
Top 5 Target | Count |
---|---|
CTLA4(Cytotoxic T-Lymphocyte-Associated Antigen 4) | 2 |
Target |
Mechanism CTLA4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BTK inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CTLA4 inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2007 |
Sponsor / Collaborator |
Start Date01 May 2004 |
Sponsor / Collaborator |
Start Date01 May 2002 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
10B-10 ( CTLA4 ) | Neoplasms More | Preclinical |
APL-509 ( CTLA4 ) | Neoplasms More | Preclinical |
DR-109 ( BTK x HER2 ) | Solid tumor More | Pending |
MEB-4906 ( μ opioid receptor ) | Pain More | Pending |